Country
Belgium
Imcyse SA has raised an additional €21.3 million in Series B financing in order to advance its pipeline of immunotherapy compounds and simultaneously brought Pfizer Inc on board as a shareholder.
Full text available to subscribers only. Click here for information on subscribing to MedNous.